James Saccaro - Baxter International Chief Financial Officer, Executive Vice President
| BAX Stock | USD 33.31 0.44 1.34% |
President
Mr. James K. Saccaro is Chief Financial Officer, Executive Vice President of the Company since 2017.
| Age | 51 |
| Tenure | 7 years |
| Address | One Baxter Parkway, Deerfield, IL, United States, 60015 |
| Phone | 224 948 2000 |
| Web | https://www.baxter.com |
James Saccaro Latest Insider Activity
Tracking and analyzing the buying and selling activities of James Saccaro against Baxter International stock is an integral part of due diligence when investing in Baxter International. James Saccaro insider activity provides valuable insight into whether Baxter International is net buyers or sellers over its current business cycle. Note, Baxter International insiders must abide by specific rules, including filing SEC forms every time they buy or sell Baxter International'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
James Saccaro over six months ago Disposition of 8998 shares by James Saccaro of GE HealthCare at 78.0 subject to Rule 16b-3 |
Baxter International Management Efficiency
The company has Return on Asset of 0.0316 % which means that on every $100 spent on assets, it made $0.0316 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.0163 %, implying that it generated $0.0163 on every 100 dollars invested. Baxter International's management efficiency ratios could be used to measure how well Baxter International manages its routine affairs as well as how well it operates its assets and liabilities. At this time, Baxter International's Return On Tangible Assets are fairly stable compared to the past year. Return On Equity is likely to rise to 0.33 in 2024, whereas Return On Capital Employed is likely to drop 0.02 in 2024. At this time, Baxter International's Non Currrent Assets Other are fairly stable compared to the past year. Intangible Assets is likely to rise to about 6.4 B in 2024, whereas Total Assets are likely to drop slightly above 16.2 B in 2024.Similar Executives
| Showing other executives | PRESIDENT Age | ||
| David Hickey | Becton Dickinson and | 60 | |
| Brian Andrews | The Cooper Companies, | 45 | |
| Patrik Eriksson | Envista Holdings Corp | 56 | |
| Aileen RuffPatry | West Pharmaceutical Services | N/A | |
| Bernard Birkett | West Pharmaceutical Services | 55 | |
| Quintin Lai | West Pharmaceutical Services | 53 | |
| Jennifer Schneiders | Hologic | 56 | |
| Robert Auerbach | The Cooper Companies, | 58 | |
| Agostino Ricupati | The Cooper Companies, | 57 | |
| Bobby Ghoshal | ResMed Inc | 52 | |
| Virginia Sanzone | ICU Medical | 49 | |
| Jan Verstreken | Hologic | 56 | |
| Andy Polywacz | West Pharmaceutical Services | N/A | |
| Eric Resnick | West Pharmaceutical Services | 55 | |
| James Ferguson | Teleflex Incorporated | N/A | |
| Thomas Spoerel | Becton Dickinson and | 45 | |
| Joseph Wright | Merit Medical Systems | 54 | |
| Karen Boylan | Teleflex Incorporated | 47 | |
| James Borzi | Becton Dickinson and | 49 | |
| Alexandre Conroy | Becton Dickinson and | 57 | |
| Holly Sheffield | The Cooper Companies, | 53 | |
Management Performance
| Return On Equity | 0.0163 | ||||
| Return On Asset | 0.0316 |
Baxter International Leadership Team
Elected by the shareholders, the Baxter International's board of directors comprises two types of representatives: Baxter International inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Baxter. The board's role is to monitor Baxter International's management team and ensure that shareholders' interests are well served. Baxter International's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Baxter International's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Andrew Frye, Senior Vice President and President APAC | ||
| David Rosenbloom, Executive Counsel | ||
| Jacqueline Kunzler, Senior Vice President and Chief Quality Officer | ||
| Nancy Schlichting, Independent Director | ||
| Brik Eyre, Senior Vice President, President - Americas | ||
| Michael Mahoney, Independent Director | ||
| Heather Knight, Executive Therapies | ||
| Stacey Eisen, Senior Communications | ||
| Charles Patel, Senior Officer | ||
| Talvis Love, Senior Officer | ||
| Amy McbrideWendell, Independent Director | ||
| John Forsyth, Independent Director | ||
| Jeanne Mason, Senior Vice President - Human Resources | ||
| Brian Stevens, Senior Vice President Chief Accounting Officer, Controller | ||
| Scott Pleau, Corporate Vice President - Operations | ||
| Cathy Smith, Independent Director | ||
| David Wilkes, Independent Director | ||
| Albert Stroucken, Lead Independent Director | ||
| James Borzi, Senior Vice President Chief Supply Chain Officer | ||
| Mba BE, Executive Pharmaceuticals | ||
| James Gavin, Independent Director | ||
| Ellen Bradford, Senior Secretary | ||
| Thomas Chen, Independent Director | ||
| Piero Novello, Senior Markets | ||
| Clare Trachtman, Vice President Investor Relations | ||
| Amy Wendell, Independent Director | ||
| Peter Hellman, Lead Independent Director | ||
| Reazur Rasul, Executive Technologies | ||
| Gerard Greco, Senior Officer | ||
| Jose Almeida, Chairman of the Board, President, Chief Executive Officer | ||
| James Saccaro, Chief Financial Officer, Executive Vice President | ||
| Thomas Stallkamp, Lead Independent Director | ||
| Patricia Morrison, Independent Director | ||
| MS MD, Senior Officer | ||
| Christopher Toth, Executive Care | ||
| Joel Grade, Executive CFO | ||
| Giuseppe Accogli, Senior Vice President and Presidentident - Global Businesses | ||
| Stephen Oesterle, Independent Director | ||
| Sean Martin, Corporate Vice President General Counsel | ||
| Cristiano Franzi, Senior Vice President and President EMEA |
Baxter Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Baxter International a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.0163 | ||||
| Return On Asset | 0.0316 | ||||
| Profit Margin | 0.01 % | ||||
| Operating Margin | 0.09 % | ||||
| Current Valuation | 28.78 B | ||||
| Shares Outstanding | 510.59 M | ||||
| Shares Owned By Insiders | 0.37 % | ||||
| Shares Owned By Institutions | 94.71 % | ||||
| Number Of Shares Shorted | 12.79 M | ||||
| Price To Earning | 27.05 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Baxter Stock Analysis
When running Baxter International's price analysis, check to measure Baxter International's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Baxter International is operating at the current time. Most of Baxter International's value examination focuses on studying past and present price action to predict the probability of Baxter International's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Baxter International's price. Additionally, you may evaluate how the addition of Baxter International to your portfolios can decrease your overall portfolio volatility.